scholarly journals AML with Renal Infiltration Manifesting as Acute Renal Failure, Diagnosed with FDG-PET CT Scan: Case Report

2021 ◽  
Vol 8 (10) ◽  
Author(s):  
Chauhan P ◽  
◽  
Gupta A ◽  
Ora M ◽  
Agrawal S ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Ct Scan ◽  
Fdg Pet ◽  
Myeloid Leukemia ◽  
Metabolic Response ◽  
Response To Therapy ◽  
Extramedullary Disease ◽  
Pet Ct ◽  
Pet Ct Scan ◽  
Acute Myeloid

Extramedullary disease in acute myeloid leukemia is a known phenomenon with reported incidence of 2.5-9.1 %. However, acute kidney injury due to direct infiltration of malignant cells is reported in only 1% cases of acute leukemia. We report a case of acute myeloid leukemia who developed acute kidney failure at presentation, was diagnosed with renal and pancreatic infiltration by FDG-PET scan and was treated successfully with hypomethylating agent and venetoclax. PET-CT scan can be a non-invasive modality for diagnosing extramedullary disease in acute myeloid leukemia and monitoring of response to therapy in these cases. Early initiation of anti-leukemia therapy in our case lead to complete metabolic response with normalization of the renal functions.

Use of 18F-FDG PET-CT for Detection of Active Disease in Acute Myeloid Leukemia

2016 ◽  
Vol 41 (3) ◽  
pp. e137-e140 ◽  
Author(s):  
Saeed Elojeimy ◽  
A. Luana Stanescu ◽  
Marguerite T. Parisi
Keyword(s):  
Acute Myeloid Leukemia ◽  
Fdg Pet ◽  
Myeloid Leukemia ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Active Disease ◽  
Acute Myeloid

scholarly journals 18F-FDG-PET/CT for detection of extramedullary acute myeloid leukemia

Haematologica ◽  
2011 ◽  
Vol 96 (10) ◽  
pp. 1552-1556 ◽  
Author(s):  
F. Stolzel ◽  
C. Rollig ◽  
J. Radke ◽  
B. Mohr ◽  
U. Platzbecker ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Fdg Pet ◽  
Myeloid Leukemia ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Acute Myeloid

Extramedullary disease in patients with acute myeloid leukemia assessed by (18)F-FDG PET

2013 ◽  
Vol 90 (4) ◽  
pp. 273-278 ◽  
Author(s):  
Anne-Sofie Weindel Ibar Cribe ◽  
Maria Steenhof ◽  
Claus Werenberg Marcher ◽  
Henrik Petersen ◽  
Henrik Frederiksen ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Fdg Pet ◽  
Myeloid Leukemia ◽  
Extramedullary Disease ◽  
Acute Myeloid

Grover Disease (Transient Acantholytic Dermatosis) in Acute Myeloid Leukemia on FDG PET/CT

2014 ◽  
Vol 39 (2) ◽  
pp. e173-e175 ◽  
Author(s):  
Hongyun June Zhu ◽  
Lindsey N. Clark ◽  
Linda A. Deloney ◽  
James E. McDonald
Keyword(s):  
Acute Myeloid Leukemia ◽  
Fdg Pet ◽  
Myeloid Leukemia ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Acute Myeloid

[ 18F]-FDG-PET/CT correlates with the response of radiorefractory thyroid cancer to lenvatinib and patients’ survival

2021 ◽  
Author(s):  
Laura Valerio ◽  
Federica Guidoccio ◽  
Carlotta Giani ◽  
Elisa Tardelli ◽  
Giulia Puccini ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Ct Scan ◽  
Fdg Pet ◽  
Metabolic Response ◽  
Whole Body ◽  
Morphological Response ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Pet Ct Scan

Abstract Introduction [18F]-FDG-PET/CT positive metastatic lesions in radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) have a poor prognosis and lenvatinib represents the best therapy. We investigated the role of [ 18F]-FDG-PET/CT in the evaluation of metabolic response and prediction of the outcome of RAI-R DTC patients treated with lenvatinib. Materials and Methods Thirty-three progressive metastatic RAI-R DTC patients treated with lenvatinib were investigated at baseline and during follow-up with biochemical (Tg/TgAb), morphological (whole-body CT scan) and metabolic evaluation ([ 18F]-FDG-PET/CT). Results Nineteen of thirty-three (57.6%) patients showed the greatest metabolic response at the first [ 18F]-FDG-PET/CT scan, performed after 4 weeks of lenvatinib, while 5/33 (15.1%) patients had this response later. Moreover, 66.7% of patients had both a metabolic response at the first [ 18F]-FDG-PET/CT scan and a morphological response at the first CT scan. We observed a correlation between the metabolic response at [ 18F]-FDG-PET/CT scan performed after 4 weeks of treatment and the biochemical response at the same time in 60.6% of patients. The median overall survival (OS) was significantly longer in patients with either a metabolic response at last [ 18F]-FDG-PET/CT (40.00 vs 8.98 months) or a morphological response at last CT scan (37.22 vs 9.53 months) than in those without response. Moreover, the OS was longer in patients with a metabolic response at [ 18F]-FDG-PET/CT performed after 4 weeks of treatment (36.53 vs 11.28 months). Conclusions Our data show that [ 18F]-FDG-PET/CT can early predict the response to lenvatinib and correlates with the OS of RAI-R DTC patients treated with this drug.

F-18 FDG PET/CT Showing Bilateral Breast Involvement in Acute Myeloid Leukemia Relapse

2009 ◽  
Vol 34 (10) ◽  
pp. 713-715 ◽  
Author(s):  
Christian von Falck ◽  
Florian Laenger ◽  
Wolfram H. Knapp ◽  
Michael Galanski
Keyword(s):  
Acute Myeloid Leukemia ◽  
Fdg Pet ◽  
Myeloid Leukemia ◽  
Pet Ct ◽  
Leukemia Relapse ◽  
Fdg Pet Ct ◽  
Acute Myeloid

scholarly journals Complete Metabolic Response in FDG-PET-CT Scan before Discontinuation of Immune Checkpoint Inhibitors Correlates with Long Progression-Free Survival

Cancers ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 2616
Author(s):  
Timo E. Schank ◽  
Andrea Forschner ◽  
Michael Max Sachse ◽  
Antonia Dimitrakopoulou-Strauss ◽  
Christos Sachpekidis ◽  
...  
Keyword(s):  
Ct Scan ◽  
Fdg Pet ◽  
Metabolic Response ◽  
Checkpoint Inhibitors ◽  
Progression Free Survival ◽  
Complete Metabolic Response ◽  
Free Survival ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Pet Ct Scan

Checkpoint inhibitors have revolutionized the treatment of patients with metastasized melanoma. However, it remains unclear when to stop treatment. We retrospectively analyzed 45 patients (median age 64 years; 58% male) with metastasized melanoma from 3 cancer centers that received checkpoint inhibitors and discontinued therapy due to either immune-related adverse events or patient decision after an (18F)2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) combined with a low-dose CT scan (FDG-PET-CT) scan without signs for disease progression. After a median of 21 (range 1–42) months of immunotherapy an FDG-PET-CT scan was performed to evaluate disease activity. In these, 32 patients (71%) showed a complete metabolic response (CMR) and 13 were classified as non-CMR. After a median follow-up of 34 (range 1–70) months, 3/32 (9%) of CMR patients and 6/13 (46%) of non-CMR patients had progressed (p = 0.007). Progression-free survival (PFS), as estimated from the date of last drug administration, was significantly longer among CMR patients than non-CMR (log-rank: p = 0.001; hazard ratio: 0.127; 95% CI: 0.032–0.511). Two-year PFS was 94% among CMR patients and 62% among non-CMR patients. Univariable Cox regression showed that metabolic response was the only parameter which predicted PFS (p = 0.004). Multivariate analysis revealed that metabolic response predicted disease progression (p = 0.008). In conclusion, our findings suggest that patients with CMR in an FDG-PET-CT scan may have a favorable outcome even if checkpoint inhibition is discontinued.

Extramedullary Acute Myeloid Leukemia and the Use of FDG-PET/CT

2009 ◽  
Vol 34 (6) ◽  
pp. 365-366 ◽  
Author(s):  
Sonali Rao ◽  
Amelia Langston ◽  
James R. Galt ◽  
Raghuveer K. Halkar
Keyword(s):  
Acute Myeloid Leukemia ◽  
Fdg Pet ◽  
Myeloid Leukemia ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Acute Myeloid
Sign in / Sign up

Export Citation Format

Share Document